Original data · Jevity Intelligence
The Peptide Evidence Index
Every peptide, ranked by what the evidence actually shows. The Jevity Score is a transparent composite of evidence strength, regulatory status and supply integrity, scored the same way for all 32 peptides so you can compare them honestly.
| # | Peptide | Category | Jevity Score | Evidence | FDA | WADA | UAE / DHA |
|---|---|---|---|---|---|---|---|
| 1 | SemaglutideOzempic, Wegovy, Rybelsus | Metabolic & weight | 100 | FDA-approved | FDA-approved (Ozempic®, Wegovy®) | Not prohibited | Prescription medicine — DHA-licensed provider |
| 2 | TirzepatideMounjaro, Zepbound | Metabolic & weight | 100 | FDA-approved | FDA-approved (Mounjaro®, Zepbound®) | Not prohibited | Prescription medicine — DHA-licensed provider |
| 3 | TesamorelinEgrifta | Growth-hormone axis | 93 | FDA-approved | FDA-approved (Egrifta®) | Prohibited at all times (GH axis) | Prescription medicine — DHA-licensed provider |
| 4 | PT-141Bremelanotide, Vyleesi | Sexual & hormonal | 93 | FDA-approved | FDA-approved (Vyleesi®) | Not prohibited | Prescription medicine — DHA-licensed provider |
| 5 | Oxytocinthe 'bonding' hormone | Cognitive & mood | 93 | FDA-approved | FDA-approved (Pitocin®) | Not prohibited | Prescription medicine — DHA-licensed provider |
| 6 | GonadorelinGnRH | Sexual & hormonal | 88 | FDA-approved | FDA-approved (diagnostic; Factrel®) | Not prohibited | Prescription medicine — DHA-licensed provider |
| 7 | Collagen PeptidesHydrolyzed collagen | Skin & cosmetic | 73 | Dietary supplement | Dietary supplement (food) | Not prohibited | Available as a supplement |
| 8 | SermorelinGHRH 1-29 | Growth-hormone axis | 68 | In human trials | Approval withdrawn (non-safety); available compounded (503A) | Prohibited at all times (GH axis) | Prescription-only via a DHA-licensed clinic |
| 9 | Thymosin Alpha-1Zadaxin | Immune | 65 | In human trials | Not FDA-approved (approved abroad as Zadaxin®); compoundable (removed Cat 2, Sep 2024) | Not prohibited | Prescription-only via a DHA-licensed clinic |
| 10 | ArgirelineAcetyl Hexapeptide-8 | Skin & cosmetic | 63 | Topical cosmetic | Cosmetic ingredient (topical) | Not prohibited | Available as a cosmetic (topical) |
| 11 | MatrixylPalmitoyl Pentapeptide-4 | Skin & cosmetic | 63 | Topical cosmetic | Cosmetic ingredient (topical) | Not prohibited | Available as a cosmetic (topical) |
| 12 | GlutathioneGSH | Longevity & cellular | 63 | Dietary supplement | Dietary supplement (oral); IV compounded | Not prohibited | Available as a supplement |
| 13 | RetatrutideTriple-G | Metabolic & weight | 58 | In human trials | Investigational — Phase 3 trials (not approved) | Not prohibited | Not available — investigational |
| 14 | Cagrilintidewith semaglutide = CagriSema | Metabolic & weight | 58 | In human trials | Investigational — Phase 3 trials (not approved) | Not prohibited | Not available — investigational |
| 15 | GHK-CuCopper Peptide | Skin & cosmetic | 58 | Topical cosmetic | Cosmetic ingredient (topical); injectable not FDA-approved | Not prohibited (topical) | Available as a cosmetic (topical) |
| 16 | Kisspeptin | Sexual & hormonal | 58 | In human trials | Investigational — human research (not approved) | Not prohibited | Not available — investigational |
| 17 | ElamipretideSS-31, MTP-131 | Longevity & cellular | 58 | In human trials | Investigational — late-stage trials (not approved) | Verify on current WADA list | Not available — investigational |
| 18 | AOD-9604GH fragment 176-191 | Metabolic & weight | 58 | In human trials | Not FDA-approved; compoundable (removed Cat 2, Sep 2024) | Verify on current WADA list | Prescription-only via a DHA-licensed clinic |
| 19 | Ipamorelin | Growth-hormone axis | 48 | Early / limited human data | Not FDA-approved; compoundable (removed from 503A Cat 2, Sep 2024) | Prohibited at all times (GH axis) | Prescription-only via a DHA-licensed clinic |
| 20 | CJC-1295with/without DAC | Growth-hormone axis | 45 | Early / limited human data | Not FDA-approved; compoundable (removed from 503A Cat 2, Sep 2024) | Prohibited at all times (GH axis) | Prescription-only via a DHA-licensed clinic |
| 21 | Selank | Cognitive & mood | 40 | Early / limited human data | Not FDA-approved; compoundable (removed Cat 2, Sep 2024); approved in Russia | Verify on current WADA list | Prescription-only via a DHA-licensed clinic |
| 22 | Semax | Cognitive & mood | 40 | Early / limited human data | Not FDA-approved — research use only; approved in Russia | Verify on current WADA list | Prescription-only via a DHA-licensed clinic |
| 23 | Hexarelin | Growth-hormone axis | 37 | Early / limited human data | Not FDA-approved — research use only | Prohibited at all times (GH axis) | Prescription-only via a DHA-licensed clinic |
| 24 | GHRP-6 | Growth-hormone axis | 37 | Early / limited human data | Not FDA-approved — research use only | Prohibited at all times (GH axis) | Prescription-only via a DHA-licensed clinic |
| 25 | EpitalonEpithalon | Longevity & cellular | 35 | Early / limited human data | Not FDA-approved — research use only | Verify on current WADA list | Prescription-only via a DHA-licensed clinic; unsupervised import restricted |
| 26 | DSIPDelta Sleep-Inducing Peptide | Cognitive & mood | 35 | Early / limited human data | Not FDA-approved — research use only | Verify on current WADA list | Prescription-only via a DHA-licensed clinic |
| 27 | BPC-157Body Protection Compound | Healing & regenerative | 28 | Animal data only | Not FDA-approved — research use only; under 503A review (PCAC Jul 2026) | Prohibited at all times | Prescription-only via a DHA-licensed clinic; unsupervised import restricted |
| 28 | TB-500Thymosin Beta-4 fragment | Healing & regenerative | 25 | Animal data only | Not FDA-approved — research use only | Prohibited at all times | Prescription-only via a DHA-licensed clinic; unsupervised import restricted |
| 29 | LL-37Cathelicidin | Immune | 25 | Animal data only | Not FDA-approved — preclinical | Verify on current WADA list | Prescription-only via a DHA-licensed clinic |
| 30 | MOTS-cMitochondrial peptide | Longevity & cellular | 25 | Animal data only | Not FDA-approved — research use only (503A review, PCAC Jul 2026) | Verify on current WADA list | Prescription-only via a DHA-licensed clinic |
| 31 | Humanin | Longevity & cellular | 25 | Animal data only | Not FDA-approved — preclinical | Verify on current WADA list | Not available — investigational |
| 32 | Dihexa | Cognitive & mood | 22 | Animal data only | Not FDA-approved — early research | Verify on current WADA list | Not available — investigational |
How the Jevity Score works
Each peptide is scored out of 100 from three components, weighted and combined transparently:
- Evidence: the strength and tier of human data, from FDA-approved trials down to animal-only or theoretical.
- Regulatory: approval and legal status across FDA, WADA and the UAE DHA framework.
- Supply integrity: whether a legitimate, quality-controlled supply exists, or whether the market is grey and unverified.
A high score means proven and accessible. A low score does not always mean useless, it means unproven, unregulated, or both, and that anyone selling it is ahead of the science. We update the Index as evidence and regulation change.
Cite this Index. Journalists, clinicians and researchers are welcome to reference it.
Explore every peptide in depth →
Jevity Peptide Evidence Index, 2026-07-20. https://jevity.io/data/peptide-evidence-index/
Educational only, not medical advice. Most therapeutic peptides are prescription or research only and require a licensed clinician. Scoring methodology is published at editorial standards. Jevity is operated by Upcapital Global FZCO, Dubai Silicon Oasis, UAE.